Contains Nonbinding Recommendations

Guidance on Loratadine

This guidance represents the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

Active ingredient: Loratadine

Form/Route: Orally Disintegrating Tablets/Oral

Recommended studies: 2 studies

1. Type of study: Fasting
   Design: Single-dose, two-way crossover \textit{in-vivo}
   Strength: 10 mg
   Subjects: Normal healthy males and females, general population.
   Additional Comments:

2. Type of study: Fed
   Design: Single-dose, two-way crossover \textit{in-vivo}
   Strength: 10 mg
   Subjects: Normal healthy males and females, general population.
   Additional comments:

Analytes to measure: Loratadine and the active metabolite, descarboethoxyloratadine, in plasma.

Please submit the metabolite data as supportive evidence of the comparable therapeutic outcome. For the metabolite, the following data should be submitted: individual and mean concentrations, individual and mean pharmacokinetic parameters, and geometric means and ratios of means for AUC and Cmax.

Bioequivalence based on (90\% CI): Loratadine

Waiver request of \textit{in-vivo} testing: Not Applicable

Dissolution test method and sampling times:

Please note that a Dissolution Methods Database is available to the public at the OGD website at http://www.fda.gov/cder/ogd/index.htm. Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.

Finalized May 2008